sellWeak cluster of 210b5-1 plan
N Anthony Coles sold $2.5M of CERE
director at Cerevel Therapeutics Holdings, Inc.. 100,000 shares at an average of $25.34, traded Nov 2, 2023, filed Nov 6, 2023.
Warning score
33Value
$2.5M
100,000 shares
Holdings after
2,704
-242% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$2.5M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-059520, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 2, 2023 | MOption exercise Common Stock10b5-1 | +38,599 | $3.50 | $135k | 41,303 | Nov 6, 2023 |
| Nov 2, 2023 | SOpen-market sale Common Stock10b5-1 | -38,599 | $25.19 | $972k | 2,704 | Nov 6, 2023 |
| Nov 3, 2023 | MOption exercise Common Stock10b5-1 | +61,401 | $3.50 | $215k | 64,105 | Nov 6, 2023 |
| Nov 3, 2023 | SOpen-market sale Common Stock10b5-1 | -61,401 | $25.43 | $1.6M | 2,704 | Nov 6, 2023 |
| Nov 2, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,599 | $0.00 | $0 | 2,613,818 | Nov 6, 2023 |
| Nov 3, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -61,401 | $0.00 | $0 | 2,552,417 | Nov 6, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.